Chikungunya vaccine shows antibody response in Phase I trial

Emily Mullin

Following recent outbreaks in the Pacific and Caribbean, virus has made its way to the U.S.–and drug developers have taken note of its continued spread.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS